Mitochondrial modulation decreases the bortezomib-resistance in multiple myeloma cells

International Journal of Cancer

Volumn 133, Issue 6, 2013, Pages 1357-1367

  Song, I S ^a   Kim, H K ^a   Lee, S R ^a   Jeong, S H ^a   Kim, N ^a   Ko, K S ^a   Rhee, B D ^a   Han, J ^a  

^a Inje University   (South Korea)

Author keywords

bortezomib; cyclophilin D; mitochondrial activity; multiple myeloma; superoxide dismutase 2

Indexed keywords

2 METHOXYESTRADIOL; ADENOSINE TRIPHOSPHATE; BORTEZOMIB; CALCIUM; CYCLOPHILIN D; MANGANESE SUPEROXIDE DISMUTASE; MITOCHONDRIAL CALCIUM UNIPORTER; MITOCHONDRIAL PROTEIN; UNCLASSIFIED DRUG;

AGED; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL FUNCTION; CELL LEVEL; CELL STRAIN KMS20; CELL STRAIN KMS28BM; CYPD GENE; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; MCU GENE; MITOCHONDRIAL GENE; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; MULTIPLE MYELOMA; MYELOMA CELL; OXYGEN CONSUMPTION; PRIORITY JOURNAL; SOD2 GENE;

BORTEZOMIB; CYCLOPHILIN D; MITOCHONDRIAL ACTIVITY; MULTIPLE MYELOMA; SUPEROXIDE DISMUTASE 2;

AGED; ANTINEOPLASTIC AGENTS; APOPTOSIS; BORONIC ACIDS; CALCIUM; CELL LINE, TUMOR; CYCLOPHILINS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; MULTIPLE MYELOMA; PYRAZINES; REACTIVE OXYGEN SPECIES; SUPEROXIDE DISMUTASE; TRANSCRIPTOME;

EID: 84879937580     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28149     Document Type: Article

References (36)

1. Otsuki T, Yamada O, Kurebayashi J, et al. Estrogen receptors in human myeloma cells. Cancer Res 2000; 60: 1434-41.
2. Chauhan D, Li G, Podar K, et al. Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells. Blood 2004; 104: 2458-66.
3. San Miguel J, Blade J, Boccadoro M, et al. A practical update on the use of bortezomib in the management of multiple myeloma. Oncologist 2006; 11: 51-61.
4. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61: 3071-6.
5. Ma MH, Yang HH, Parker K, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003; 9: 1136-44.
6. Landowski TH, Megli CJ, Nullmeyer KD, et al. Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines. Cancer Res 2005; 65: 3828-36.
7. Gu H, Chen X, Gao G, et al. Caspase-2 functions upstream of mitochondria in endoplasmic reticulum stress-induced apoptosis by bortezomib in human myeloma cells. Mol Cancer Ther 2008; 7: 2298-307.
8. Gomez-Bougie P, Wuilleme-Toumi S, Menoret E, et al. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma. Cancer Res 2007; 67: 5418-24.
9. Smit LA, Hallaert DY, Spijker R, et al. Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity. Blood 2007; 109: 1660-8.
10. Caldera H, Giralt S,. Stem cell transplantation for multiple myeloma: current status and future directions. Curr Hematol Rep 2004; 3: 249-56.
11. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-17.
12. Richardson PG, Hideshima T, Mitsiades C, et al. The emerging role of novel therapies for the treatment of relapsed myeloma. J Natl Compr Canc Netw 2007; 5: 149-62.
13. Richardson PG, Sonneveld P, Schuster MW, et al. Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. Br J Haematol 2007; 137: 429-35.
14. Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006; 24: 3113-20.
15. Lonial S, Waller EK, Richardson PG, et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 2005; 106: 3777-84.
16. Gogvadze V, Orrenius S, Zhivotovsky B,. Mitochondria in cancer cells: what is so special about them? Trends Cell Biol 2008; 18: 165-73.
17. Warburg O,. On the origin of cancer cells. Science 1956; 123: 309-14.
18. Shaw RJ,. Glucose metabolism and cancer. Curr Opin Cell Biol 2006; 18: 598-608.
19. Otsuki T, Yamada O, Yata K, et al. Genetic and biological characterization of human myeloma cell lines: an overwiew of the lines established at Kawasaki Medical School. Gene Funct Dis 2000; 1: 48-56.
20. Inoue J, Otsuki T, Hirasawa A, et al. Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma. Am J Pathol 2004; 165: 71-81.
21. Keats JJ, Fonseca R, Chesi M, et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007; 12: 131-44.
22. Schriner SE, Linford NJ, Martin GM, et al. Extension of murine life span by overexpression of catalase targeted to mitochondria. Science 2005; 308: 1909-11.
23. Kurosu T, Tsuji K, Kida A, et al. Rottlerin synergistically enhances imatinib-induced apoptosis of BCR/ABL-expressing cells through its mitochondrial uncoupling effect independent of protein kinase C-delta. Oncogene 2007; 26: 2975-87.
24. To MS, Aromataris EC, Castro J, et al. Mitochondrial uncoupler FCCP activates proton conductance but does not block store-operated Ca(2+) current in liver cells. Arch Biochem Biophys 2010; 495: 152-8.
25. Nakagawa T, Shimizu S, Watanabe T, et al. Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature 2005; 434: 652-8.
26. Suzuki K, Murtuza B, Sammut IA, et al. Heat shock protein 72 enhances manganese superoxide dismutase activity during myocardial ischemia-reperfusion injury, associated with mitochondrial protection and apoptosis reduction. Circulation 2002; 106: I270-6.
27. Fulda S, Galluzzi L, Kroemer G,. Targeting mitochondria for cancer therapy. Nat Rev Drug Discov 2010; 9: 447-64.
28. Sterz J, von Metzler I, Hahne JC, et al. The potential of proteasome inhibitors in cancer therapy. Expert Opin Investig Drugs 2008; 17: 879-95.
29. Franke NE, Niewerth D, Assaraf YG, et al. Impaired bortezomib binding to mutant beta5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells. Leukemia 2012; 26: 757-68.
30. Podar K, Gouill SL, Zhang J, et al. A pivotal role for Mcl-1 in Bortezomib-induced apoptosis. Oncogene 2008; 27: 721-31.
31. Brown GC,. Control of respiration and ATP synthesis in mammalian mitochondria and cells. Biochem J 1992; 284 (Pt 1): 1-13.
32. Brookes PS, Yoon Y, Robotham JL, et al. Calcium, ATP, and ROS: a mitochondrial love-hate triangle. Am J Physiol Cell Physiol 2004; 287: C817-33.
33. Honda HM, Korge P, Weiss JN,. Mitochondria and ischemia/reperfusion injury. Ann N Y Acad Sci 2005; 1047: 248-58.
34. Ye XQ, Wang GH, Huang GJ, et al. Heterogeneity of mitochondrial membrane potential: a novel tool to isolate and identify cancer stem cells from a tumor mass? Stem Cell Rev 2011; 7: 153-60.
35. Kim HK, Park WS, Kang SH, et al. Mitochondrial alterations in human gastric carcinoma cell line. Am J Physiol Cell Physiol 2007; 293: C761-71.
36. Schinzel AC, Takeuchi O, Huang Z, et al. Cyclophilin D is a component of mitochondrial permeability transition and mediates neuronal cell death after focal cerebral ischemia. Proc Natl Acad Sci USA 2005; 102: 12005-10.